Thursday 13 October 2005

ConjuChem Announces New President and CEO

MARK D. PERRIN TO ASSUME RESPONSBILITIES EFFECTIVE OCTOBER 17TH

Montreal, Canada, October 13, 2005 -- ConjuChem Inc. (TSX: CJC) today announced the appointment of Mark D. Perrin as president and CEO, effective October 17th 2005. Outgoing president and interim CEO Jacques Lapointe will remain as executive chairman.

"Mark's substantial operating experience will enable him to guide ConjuChem through its next phase of growth," said Jacques Lapointe. "As incoming president and CEO, his priority will be to focus the company around the delivery of key clinical and commercial milestones. His appointment reinforces ConjuChem's commitment to building long-term value for our shareholders."

Mr. Perrin's professional achievements to date are substantial. As the Executive Vice President and Chief Commercial Officer at Orphan Medical, he was responsible for all business development, marketing and sales activities. Previously, as Executive Vice President of Commercial Operations at COR Therapeutics, he played the lead role in establishing the company's commercial infrastructure. Prior to that, Mr. Perrin held progressively senior management roles in the pharmaceutical industry including Division Manager, Lederle Canada, Vice President & General Manager, Lederle Laboratories (U.S.) and Vice President, Marketing and Sales for the U.S. at Burroughs Wellcome. He holds a B.S. from Fordham University and a M.B.A. from the Kellogg Graduate School of Northwestern University.

"The fundamental science behind ConjuChem and the inherent value proposition that it offers to the drug development community -- long-lasting safe compounds -- are compelling. They represent the kind of innovation that is in high demand," said Mark Perrin. "My entire professional career has focused on leadership and commercial operations in the pharmaceutical space. I intend to bring this skill set and passion to ConjuChem as we translate this exciting science into tangible, commercial fundamentals."

About ConjuChem

ConjuChem, developers of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic DAC^TM Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide. The Company is developing compounds to treat various disorders including diabetes, human growth deficiencies, HIV/AIDS, and congestive heart failure.

Detailed descriptions of the Company can be viewed on the Company's website www.conjuchem.com.